Eli Lilly submitted a new drug application for orforglipron, its once-daily oral GLP-1 receptor agonist, following positive phase 3 results that demonstrated sustained weight loss and glycemic control comparable to weekly injectables. The drug benefits from a Commissioner's National Priority Review Voucher, which shortens the review window to as little as two months versus the standard 10–12 month timeline. Analysts project that, if approved in early 2026, orforglipron could capture a significant share of the obesity and type 2 diabetes markets by attracting patients reluctant to initiate injectable regimens.

In October, Eli Lilly announced plans to invest more than $1 billion in India to bolster its manufacturing network for complex biologics and injectables. Rather than building wholly owned facilities, the company will contract with local partners specializing in fill-finish operations and high-potency active pharmaceutical ingredients. This strategic move aims to secure supply for blockbuster therapies such as tirzepatide and support anticipated global demand growth in both diabetes and obesity segments.

Eli Lilly declared its quarterly dividend at $1.73 per share, marking the 11th consecutive annual increase and reflecting a compound annual growth rate of approximately 16% over the past five years. With a payout ratio near 44% of earnings, the company maintains ample capacity for future hikes. Although the current yield stands at around 0.6%, long-term investors benefit from rising yield-on-cost metrics, which have climbed above 4% for shareholders who held through the past half decade.